Multicenter retrospective evaluation of the influence of bridging therapy on efficacy of CAR T cells in aggressive lymphoma

Multicenter retrospective evaluation of the influence of bridging therapy on efficacy of CAR T cells in aggressive lymphoma - BRIDGE-CART

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038071

Enrollment

480

Registered

2025-11-19

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C83.3

Interventions

Group 1: In patients who receive autologous CAR T cells, i.e., their own cells, peripheral blood cells are first collected. After successful cell collection, the body's own T cells are purified and co

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Lymphoma treated with CD19 CAR T cells from 2019 till today

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Progression-free Survivial Observation period January 2019 to October 2025	—

Secondary

Measure	Time frame
Overallsurvival, Mortality, Toxicity, Response to Bridging before CART	—

Countries

Austria, Germany

Contacts

Public ContactFabian Müller

Universitätsklinik Erlangen, Abteilung für Innere Medizin 5 - Hämatologie und Onkologie

fabian.mueller@uk-erlangen.de+4991318543107

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026